S

Sanofi

Global pharma company; vaccines and R&D

Key Account Manager Rhinology

Full-TimeUpdated on 10/15/2026Deadline 10/25/26
No salary listed
Senior
Bachelor's
Dubai - United Arab Emirates
In Person
Sales & Account ManagementAccount Management

About the job

Requirements
  • A Bachelor of Science degree in Pharmacy or Medicine is required.
  • At least 5 years of experience in pharmaceutical industry sales is required.
  • Key Account Management knowledge is required.
  • Knowledge of access and new product inclusion processes is required.
  • Basic marketing knowledge is required.
  • Analytical skills are required.
  • Project management skills are required.
  • Communication and negotiation skills are required.
  • Stakeholder management skills are required.
  • Scientific acumen is required.
Responsibilities
  • Drive performance for the assigned Dupixent chronic rhinosinusitis with nasal polyps indication, build and maintain business partnerships with key stakeholders, and ensure accessibility in key accounts.
  • Ensure the assigned brand's indication, positioning, and product accessibility; maximize sales volumes in line with company strategies and local regulations; implement launch and tactical marketing plans within the local strategy and agreed budget; assess and mitigate business risks.
  • Identify customers, map accounts and patient journeys, and educate stakeholders about asthma and its impact.
  • Implement customer targeting and profiling to maximize sales and identify account-level listing opportunities for Dupixent.
  • Coordinate with medical and marketing teams to develop tactical plans that scale product penetration and ensure product availability.
  • Develop and maintain relationships with key opinion leaders at country and regional levels to increase market presence for assigned products.
  • Oversee post-launch sales promotion to target doctors and achieve monthly, quarterly, and annual targets in line with company strategy.
  • Provide healthcare professionals with quality medical information about Dupixent in compliance with professional ethics and company rules.
  • Develop weekly and monthly customer visit plans with the line manager and follow internal sales systems and procedures.
  • Visit customers regularly to monitor product availability and movement.
  • Maintain and update product and competitor knowledge, and build relationships with trade personnel.
  • Gather ongoing market intelligence, assess its impact on company operations, and recommend timely action plans.
  • Execute marketing tactics using sales techniques and operational tools to meet sales objectives and improve selling skills and knowledge.
  • Update doctor cards and lists with required information.
  • Liaise with key opinion leaders, gather market feedback, and report relevant information to the line manager.
  • Participate in projects as required.
  • Analyze Dupixent performance, identify growth opportunities, and provide management with solutions to address challenges.
  • Build and maintain account-level partnerships with healthcare professionals, key thought leaders, tender parties, and clinical pharmacists to position Genzyme as a strategic partner.
  • Assess and mitigate business risks involving price cuts, competitor threats, and alternative sources of supply.
  • Perform business activities in accordance with industry ethics and company policies and procedures.
  • Visit customers and participate in symposiums, congresses, and meetings to increase product market presence.
  • Network with field and non-field sales colleagues to obtain support and feedback on product strategy.
  • Analyze the competitive environment and prepare counter-plans for marketing products and achieving targets.
  • Prepare and submit monthly activity reports to the marketing lead and manager, market-share reports, and CRM reports covering activity and market trends or updates.
  • Follow the internal Code of Ethics and maintain professional conduct in accordance with company procedures.
  • Maintain knowledge of relevant ethics, governance, company policies, procedures, and legal requirements, apply them to the work, and seek support or escalate decisions when needed.
  • Follow company safety rules and procedures, report accidents, incidents, and near misses, assist with accident investigations, and comply with safety documentation.
Desired Qualifications
  • Business education is a plus.
  • Specialty Care experience is a plus.
  • At least 2 years of experience with Abu Dhabi ENT doctors is a plus.

About the company

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 10, 2026 FDA approval of Sarclisa Escena created the first on-body cancer injector.
  • June 13, 2026 FDA accelerated approval expanded Tzield into recently diagnosed stage 3 T1D.
  • Q2 2026 sales grew 17.8% at CER, with Dupixent and Beyfortus leading.

What critics are saying

  • Texas sued Sanofi on February 19, 2026 over provider bribery and Medicaid fraud.
  • Sanofi sued Pfizer and Moderna on July 15, 2026, extending costly mRNA patent warfare.
  • Dupixent concentration makes 2030s patent loss an existential revenue shock.

What makes Sanofi unique

  • Dupixent reached €5.2 billion quarterly sales in Q2 2026 across nine indications.
  • October 1, 2026, Sanofi and Regeneron added four long-acting antibodies to their Alliance.
  • Sanofi's 61-project pipeline spans immunology, rare diseases, vaccines, neurology, and oncology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Professional Development Budget
  • Parental Leave

Company News

Associated Press
Oct 19th, 2026
Enable Injections wins first Japan approval for enFuse on-body injector via Sanofi's CirCLIQ

Enable Injections has won its first commercial product approval in Japan. The country's Ministry of Health, Labour and Welfare approved the company's enFuse On-Body Delivery System through Sanofi's CirCLIQ Injector. The device delivers a subcutaneous form of Sarclisa (isatuximab) with the push of a button, for treating multiple myeloma. It is the first anticancer treatment given through an on-body injector in Japan. The approval follows recent clearances in the US and Europe. Japan approved Sarclisa SC in June 2026, backed by the IRAKLIA phase 3 study, which showed the subcutaneous form was non-inferior to intravenous delivery. "We're proud to partner with Sanofi to bring our enFuse technology to patients in Japan," said Michael D. Hooven, chairman and chief executive officer of Enable.

Yahoo Finance
Oct 1st, 2026
Sanofi, Regeneron expand alliance in up to $8B deal for immunology drugs

France's Sanofi and US-based Regeneron Pharmaceuticals will expand their 20-year partnership to jointly develop and market immunology medicines in a deal worth up to $8 billion. Regeneron will receive $1 billion upfront, with potential additional payments of up to $7 billion tied to development, regulatory, and commercial targets. The collaboration will add four next-generation immunology drug candidates invented by Regeneron, with one currently in early-stage trials for eczema. The companies will equally share development costs and future profits from new drugs, whilst their existing profit-sharing agreement for top-selling medicine Dupixent remains unchanged. The deal settles prior litigation between the companies and marks an early move by Sanofi's new chief executive Belen Garijo to strengthen the company's pipeline.

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Vicebio

Sanofi completes acquisition of Vicebio Paris, December 4, 2025. Sanofi announces the completion of its acquisition of Vicebio Ltd (“Vicebio”). This acquisition brings an early-stage combination...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Blueprint Medicines

Sanofi completes acquisition of Blueprint Medicines Paris, July 18, 2025. Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes the acquisition of Dynavax

Sanofi completes the acquisition of Dynavax Paris, February 10, 2026. Sanofi today announced that it has completed the acquisition of Dynavax Technologies Corporation (Dynavax). The acquisition...